<i>miR-15</i> and <i>miR-16</i> induce apoptosis by targeting BCL2
Amelia CimminoCenter for Cancer ResearchGeorge A. CalinDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Muller FabbriCenter for Cancer ResearchMarilena V. IorioDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Manuela FerracinCenter for Cancer ResearchMasayoshi ShimizuDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Sylwia E. WojcikDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Rami I. AqeilanCenter for Cancer ResearchSimona ZupoCenter for Cancer ResearchMariella DonoCenter for Cancer ResearchLaura Z. RassentiDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Hansjüerg AlderDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Stefano VoliniaDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Chang‐Gong LiuDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Thomas J. KippsDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Massimo NegriniDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093Carlo M. CroceDepartment of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210; Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy; Diagnostics of Lymphoproliferative Diseases, Instiuto Nazionale per la Ricerca sul Cancro, Oncologia Medica C, Genoa 16123, Italy; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093
2005en
Ochiq kirishYashil
ABI
Annotatsiya
Chronic lymphocytic leukemia (CLL) is the most common human leukemia and is characterized by predominantly nondividing malignant B cells overexpressing the antiapoptotic B cell lymphoma 2 (Bcl2) protein. miR-15a and miR-16-1 are deleted or down-regulated in the majority of CLLs. Here, we demonstrate that miR-15a and miR-16-1 expression is inversely correlated to Bcl2 expression in CLL and that both microRNAs negatively regulate Bcl2 at a posttranscriptional level. BCL2 repression by these microRNAs induces apoptopsis in a leukemic cell line model. Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba